ArticleDiscover oncology2026
Global disparities in liver cancer burden: an epidemiological and socioeconomic analysis using GBD 1990-2021 data.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preclinical Evaluation of Triptophenolide-Induced Apoptosis in Hepatoblastoma (HepG2) and Hepatocellular Carcinoma (HuH7) Cell Lines.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLiver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma as defined in the Global Burden of Disease (GBD) framework, remains a major contributor to global disease burden with pronounced socioeconomic disparities. However, long-term global patterns, socioeconomic gradients, and their demographic and epidemiological drivers remain incompletely characterized. This study assessed global and regional trends in liver cancer burden using GBD 2021 data.
methodsLiver cancer disability-adjusted life years (DALYs) were estimated for 204 countries from 1990 to 2021. Temporal trends and contributing factors were examined using Joinpoint regression, age-period-cohort analysis, decomposition analysis, and frontier analysis.
resultsGlobally, liver cancer DALYs declined between 1990 and 2021, with an average annual percent change (AAPC) of - 0.46. Declines were observed in high SDI (AAPC - 0.42), high-middle SDI (- 0.63), middle SDI (- 0.72), and low SDI regions (- 0.80), whereas low-middle SDI countries experienced a modest increase (AAPC 0.08). Decomposition analysis showed that population growth and aging were the primary drivers of global DALY increases, while epidemiological changes accounted for most declines in high SDI regions. Risk factor-specific analyses revealed declining hepatitis B-attributable DALYs globally (AAPC - 0.79), contrasted by rising MASH-attributable DALYs (AAPC 0.60), particularly in low-middle SDI countries. Frontier analysis demonstrated substantial cross-country variability in performance at comparable socioeconomic levels.
conclusionGlobal liver cancer burden has declined overall but remains unevenly distributed, driven by divergent demographic transitions, etiologic profiles, and socioeconomic context. These findings highlight substantial unrealized potential for burden reduction, particularly in low and low-middle SDI countries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.